Article Information
History
- May 24, 2022.
Article Versions
- You are currently viewing Version 1 of this article (May 24, 2022 - 17:05).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Laxmikant Wali1,5,
- Michael Karbiener2,5,
- Scharon Chou1,
- Vitalii Kovtunyk1,
- Adam Adonyi1,
- Irene Gösler3,
- Ximena Contreras1,
- Delyana Stoeva1,
- Dieter Blaas3,
- Johannes Stöckl4,
- Thomas R. Kreil2,
- Guido A. Gualdoni1 and
- Anna-Dorothea Gorki1,6
- 1G.ST Antivirals GmbH, Austria
- 2Global Pathogen Safety, Takeda Manufacturing Austria AG, Austria
- 3Center of Medical Biochemistry, Max Perutz Labs, Vienna Biocenter, Medical University of Vienna, Austria
- 4Institute of Immunology, Center of Pathophysiology, Immunology & Infectiology, Medical University of Vienna, Austria
- ↵6Corresponding author, Corresponding Author: Anna-Dorothea Gorki, PhD, G.ST Antivirals GmbH, Doktor-Bohr-Gasse 7 (VBC6) 1030 Vienna, Austria, Phone: +43 6641869461, E-mail: anna-dorothea.gorki{at}gst-antivirals.com
↵5 Contributed equally